Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Screening strategy for non-alcoholic fatty liver disease

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(Suppl):S103-S122. Published online November 30, 2022

DOI: https://doi.org/10.3350/cmh.2022.0336

View: 1782 Download: 146 Citation: 1

Editorial

Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?

Heejoon Jang, Won Kim

Clin Mol Hepatol. 2023;29(2):381-383. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0088

View: 674 Download: 35

Letter to the Editor

Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs

Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):269-272. Published online February 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0040

View: 2901 Download: 258 Citations: 4

Editorial

Metabolic disease as a risk of hepatocellular carcinoma

Naoshi Nishida

Clin Mol Hepatol. 2021;27(1):87-90. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0302

View: 3530 Download: 98 Citations: 10

Review

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

Kyung-Soo Kim, Byung-Wan Lee

Clin Mol Hepatol. 2020;26(4):430-443. Published online August 14, 2020

DOI: https://doi.org/10.3350/cmh.2020.0137

View: 7392 Download: 403 Citations: 27

1 |

Viewed By 4176	Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
Viewed By 3582	Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection
Viewed By 2859	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Viewed By 2810	Recent updates on the management of autoimmune hepatitis
Viewed By 2728	Identification of high-risk subjects in nonalcoholic fatty liver disease

Cited By 99	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 42	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
Cited By 42	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 40	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 38	The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future

Search